TriSalus Life Sciences Reports Q2 2026 Financial Results with Revenue Increase and Strategic Advancements

TriSalus Life Sciences, Inc. reported its financial results for the second quarter of 2026, revealing a slight increase in revenue and a continued focus on expanding its oncology-focused product offerings. The company generated $11.4 million in revenue for the three months ended June 30, 2026, a 1.7% increase from $11.2 million in the same period last year. For the first half of 2026, total revenue was $20.3 million, down marginally from $20.4 million in the prior year. The gross profit for the second quarter was $9.9 million, reflecting a gross margin of 86.8%, up from 83.9% in the previous year, primarily due to a reduction in the cost per unit sold of its TriNav infusion systems.

Operating expenses for the second quarter increased significantly, with sales and marketing expenses rising by 59.4% to $11.4 million, attributed to expanded marketing efforts and sales force growth. Research and development expenses decreased by 14.5% to $3.1 million, while general and administrative costs fell by 12.7% to $5.2 million. The company reported a net loss of $9.2 million for the quarter, compared to a loss of $8.3 million in the same quarter of 2025. For the first half of 2026, the net loss was $7.6 million, a notable improvement from a loss of $18.7 million in the prior year.

TriSalus has made strategic advancements, including the launch of new products within its TriNav family, which are designed to enhance therapeutic delivery for various solid tumors. The company also initiated a registry study called PROTECT, aimed at expanding its market reach. As of June 30, 2026, TriSalus had 61.6 million shares of common stock outstanding, reflecting its ongoing efforts to raise capital through public offerings, which generated approximately $42.6 million in net proceeds earlier this year.

The company’s cash and cash equivalents increased to $46.3 million as of June 30, 2026, up from $20.4 million at the end of 2025. This increase was primarily due to the successful public offering of shares. However, TriSalus continues to face challenges, including the need for additional capital to fund ongoing operations and research initiatives. The company has indicated that it may need to raise further funds through equity or debt financing to support its long-term business strategy.

Looking ahead, TriSalus remains focused on the commercialization of its TriNav infusion systems and the development of its investigational immunotherapeutic, nelitolimod. The company is actively seeking partnerships to advance its clinical trials and is optimistic about the potential for future growth, despite the inherent risks and uncertainties in the biotechnology sector.